Opill’s FDA Approval: Implications for Pharmaceutical Regulation and Access to Care
Bill of Health
SEPTEMBER 12, 2023
By James René Jolin and Susannah Baruch On July 13, 2023, the United States Food and Drug Administration (FDA) approved Opill (norgestrel) as the first daily oral contraceptive available for non-prescription use in the U.S. While the timeline for availability and price of Opill will ultimately be set by its manufacturer, Perrigo, this recent move represents a significant step forward in improving access to contraceptive health care.
Let's personalize your content